ホーム › 膠腫 › ニューヨーク

ニューヨークにおける膠腫の臨床試験

ニューヨーク内の拠点で、膠腫に関する28件の研究が参加者を募集しています。

ニューヨーク内の都市

公式研究テキスト（英語）

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Albany Medical Center, Albany
Roswell Park Cancer Institute, Buffalo
The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
他4件

被験者募集中第1/2相

12 Months – 21 Years · 全性別 · 2026/10/01更新 · NCT05099003

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Northwell Health Center for Advanced Medicine - Brain Tumor Center, Lake Success
Columbia University Irving Medical Center, New York
Montefiore Medical Center, The Bronx

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/28更新 · NCT07326566

A Study of Mirdametinib in People With Central Nervous System Tumors

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
他1件

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/03更新 · NCT07539441

Glioma Developmental and HyperActive Ras Tumor (DHART) Board

Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack
Memorial Sloan Kettering West Harrison (All Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
他1件

被験者募集中観察研究

18歳以上 · 全性別 · 2026/08/31更新 · NCT05489783

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

NYU Langone Health, New York
Icahn School of Medicine at Mount Sinai, New York
Columbia University Medical Center, New York
他2件

被験者募集中第3相

18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

New York University, New York

被験者募集中第1相

1歳〜25歳 · 全性別 · 2026/08/18更新 · NCT04485559

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Research Site, New York
Research Site, New York

被験者募集中第1/2相

18歳〜130歳 · 全性別 · 2026/08/12更新 · NCT05417594

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

New York Presbyterian Hospital-Columbia University Medical Center, New York

被験者募集中第4相

18歳以上 · 全性別 · 2026/08/11更新 · NCT07486713

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

NYU Langone Health, New York

被験者募集中第1相

18歳以上 · 全性別 · 2026/07/30更新 · NCT07464925

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Columbia University Irving Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York

被験者募集中第2相

8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
他1件

被験者募集中第2相

18歳以上 · 全性別 · 2026/07/22更新 · NCT05188508

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

NYU Langone Health, New York

被験者募集中

18歳〜85歳 · 全性別 · 2026/07/21更新 · NCT06910306

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Memorial Sloan Kettering Cancer Center, New York

被験者募集中第1/2相

1歳〜26歳 · 全性別 · 2026/07/10更新 · NCT06712875

Chronic CED of TPT for Recurrent Malignant Glioma

Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York

被験者募集中第1相

18歳以上 · 全性別 · 2026/06/15更新 · NCT06666712

A Study of 177Lu-PSMA-617 in People With Gliomas

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
他1件

被験者募集中第1相

18歳以上 · 全性別 · 2026/06/04更新 · NCT07223034